Breaking Down SG&A Expenses: TG Therapeutics, Inc. vs MiMedx Group, Inc.

SG&A Expenses: A Decade of Strategic Spending

__timestampMiMedx Group, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20149048000024518692
Thursday, January 1, 201513338400019886580
Friday, January 1, 201617999700012631689
Sunday, January 1, 201722011900021977998
Monday, January 1, 201825852800020759000
Tuesday, January 1, 201919820500020838000
Wednesday, January 1, 2020181022000121812000
Friday, January 1, 2021198359000152137000
Saturday, January 1, 202220878900083231000
Sunday, January 1, 2023211124000122706000
Loading chart...

Igniting the spark of knowledge

A Comparative Analysis of SG&A Expenses: TG Therapeutics, Inc. vs MiMedx Group, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of TG Therapeutics, Inc. and MiMedx Group, Inc. from 2014 to 2023. Over this period, MiMedx Group consistently outspent TG Therapeutics, with SG&A expenses peaking at approximately 258 million in 2018. In contrast, TG Therapeutics saw a significant rise in 2021, with expenses reaching around 152 million, marking a 600% increase from 2014. This trend highlights MiMedx's aggressive market strategy, while TG Therapeutics' recent surge suggests a shift towards expansion. As the industry continues to grow, these financial insights provide a window into the strategic priorities of these companies, offering investors and analysts a deeper understanding of their operational dynamics.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025